Undiagnosed Sleep Disorder Market Offers Growth Opportunities

There are more than 70 different sleep disorders but the most common ones include insomnia, sleep apnea, restless legs syndrome, and narcolepsy. One of the fastest growing sector in the sleep disorder treatment market is obstructive sleep apnea (OSA) products. OSA affects up to 18 million patients in the US with as many as 85% are undiagnosed. Similarly, 30 million are chronic sufferers of insomnia but only a third of chronic sufferers are receiving treatment. A key reason for this low percentage of people receiving treatment is the side effects associated with most of the insomnia drugs. Over 1.6 million Americans use some form of alternative medicine to treat insomnia.

With rising awareness of sleep disorders, more people are undergoing tests to understand the basics of their sleep disorder condition. Hospitals are opening new sleep centers and upgrading old ones. Patients are looking at innovative aspects in sleep centers which make them feel more homely.

Pharma companies are coming up with new sleeping disorder drugs. Gamma Aminobutyric Acid (GABA) agents dominate the insomnia market. More than a dozen insomnia drugs are in phase II and phase III clinical trials. Major products are Ambien, Ambien CR, Lunesta, Temazepam, and Zolpidem. Respironics and ResMed are the leading competitors in the continuous positive airway pressure (CPAP) market.

The report analyzes the sleep disorder treatment market. The focus is on OSA and insomnia treatment products. The report also profiles the major companies, with a discussion of their key business strategies. It also analyzes the major market and demographic trends prevalent in the sleep disorder treatment market.